Terns Completes $87 Million Financing to Advance Three NASH Candidates

Terns Pharma, a San Mateo-Shanghai biopharma, completed a $87 million Series C round to support its three lead NASH programs. The financing was led by Deerfield Management Company and included a strategic equity investment from Eli Lilly. In 2018, Terns was founded with three small molecule targeted therapies for NASH that it in-licensed from Lilly and also an initial $30 million Lilly investment. Terns has development teams in California and Shanghai , though it plans to commercialize its products mainly in China . More details.... Share this with colleagues: // //